Multivalent live vector vaccine against Clostridium difficile-associated disease
US10046040B2 · kind B2 · utility
9Cited by
12References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 16, 2010 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Apr 15, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD/A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD/B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.